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The aim was to investigate the efficacy of neoadjuvant docetaxel–cisplatin and identify prognostic factors for outcome in locally
advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled)
underwent tumour resection after three 3-week cycles of docetaxel 85mgm
 2 (day 1) plus cisplatin 40 or 50mgm
 2 (days 1 and 2).
Therapy was well tolerated (overall grade 3 toxicity occurred in 48% patients; no grade 4 nonhaematological toxicity was reported),
with no observed late toxicities. Median overall survival (OS) and event-free survival (EFS) times were 35 and 15 months,
respectively, in the 75 patients who underwent surgery; corresponding figures for all 90 patients enrolled were 28 and 12 months. At
3 years after initiating trial therapy, 27 out of 75 patients (36%) were alive and tumour free. At 5-year follow-up, 60 and 65%
of patients had local relapse and distant metastases, respectively. The most common sites of distant metastases were the lung (24%)
and brain (17%). Factors associated with OS, EFS and risk of local relapse and distant metastases were complete tumour resection
and chemotherapy activity (clinical response, pathologic response, mediastinal downstaging). Neoadjuvant docetaxel–cisplatin was
effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.
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Surgery remains the best standard therapy for localised lung
cancer. Results from randomised studies of early stage resectable
non-small-cell lung cancer (NSCLC) have shown improved
survival from use of adjuvant chemotherapy (Non-small Cell Lung
Cancer Collaborative Group, 1995; Arriagada et al, 2004; Strauss
et al, 2004; Winton et al, 2004; Douillard et al, 2005). Improve-
ments in 5-year survival of 12–15% have been observed with
adjuvant platinum-based doublet regimens in early stage disease
(stage IB–IIIA) (Strauss et al, 2004; Winton et al, 2004; Douillard
et al, 2005), and adjuvant chemotherapy is now considered the
standard of care after radical surgical resection. However, the
associated toxicity and subjective poor tolerance of adjuvant
chemotherapy are a major limitation. Patient and physician
compliance is low and even in trials only 35–85% of targeted
dose intensity has been achieved. Moreover, a large randomised
intergroup trial failed to demonstrate any survival advantage when
cisplatin and etoposide were added to postoperative radiation,
compared with radiation alone for resected stage II–IIIA disease
(Keller et al, 2000).
Several small randomised studies (Pass et al, 1992; Rosell et al,
1994; Roth et al, 1994) have demonstrated a benefit from
neoadjuvant treatment in locally advanced disease (stage IIIA).
In a large trial involving 355 patients with stage IB–IIIA NSCLC, a
trend towards survival benefit was seen from neoadjuvant
chemotherapy (median survival 37 months vs 26 months for
surgery alone; P¼0.15) (Depierre et al, 2002). Encouragingly,
preoperative chemotherapy appears to be better tolerated than
adjuvant chemotherapy, with a high compliance of 90–95%
(Depierre et al, 2002; Betticher et al, 2003). Similarly, preliminary
results of a recent randomised trial of preoperative chemotherapy
(paclitaxel and carboplatin) have shown a nonsignificant trend
towards improved progression-free survival and overall survival
(OS) (Pisters et al, 2005).
The routine use of neoadjuvant chemotherapy in NSCLC
remains controversial. Identification of predictive/prognostic
factors to select patients who would derive the greatest
benefit from combined modality therapy will help clarify
the most appropriate clinical use of neoadjuvant chemotherapy,
particularly for patients with stage IIIA disease. We report
here the final and updated results of a large phase II trial
in patients with pN2 (proven by mediastinoscopy) stage IIIA
(International Union Against Cancer, UICC) disease.
Analyses of potential factors associated with the development
of local relapse and distant metastases are also presented.
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Patient characteristics
Initial results of this prospective, multicentre, phase II trial of
docetaxel–cisplatin induction chemotherapy have been reported
previously (Betticher et al, 2003). Briefly, all patients were required
to have mediastinoscopically proven, previously untreated, oper-
able stage IIIA (T1–3 pN2 M0) NSCLC. Eligibility criteria
included: age 18–75 years; World Health Organization (WHO)
performance status (PS) p2; forced expiratory volume X1.2ls
 1;
normal cardiac and bone marrow (leucocyte 44.0 10
9l
 1,
platelet 4100 10
9l
 1) functions and adequate hepatic (bilirubin
within normal limits, aspartate aminotransferase and alanine
aminotranferase p1.5 upper limit of normal (ULN), alkaline
phosphatase p2.5 ULN) and kidney (creatinine clearance
460mlmin
 1) functions. The trial was approved by the local
ethics committee at each participating centre, with informed,
written consent obtained from all patients.
Combined modality therapy
Patients were scheduled to receive cisplatin 80mgm
 2 as a 1-h
infusion (divided over 2 days, on days 1 and 2) plus docetaxel
85mgm
 2 as a 1-h infusion on day 1, every 3 weeks for three
cycles providing haematological function was adequate (neutrophil
41.5 10
9l
 1, platelet 4100 10
9l
 1). In view of the low toxicity
observed in the first 36 patients, the protocol was subsequently
amended to increase the dose of cisplatin to 100mgm
 2
(50mgm
 2 on days 1 and 2) from patient 37 onwards. Resection
was performed if there was no progressive disease (PD) based on
post-induction computed tomography (CT) scan and no contra-
indication emerging from pulmonary function testing. Post-
operative mediastinal radiotherapy was to be administered to
patients with positive resection margin (R1 and R2) and/or
involvement of the uppermost mediastinal lymph node. A daily
dose of 2Gy delivered in the central axis at the mid-plane was
administered 5 days/week to a cumulative dose of 60Gy. The
irradiated field included the bronchial stump, ipsilateral hilum and
vascular shadows of the mediastinum bilaterally. Postoperative
chemotherapy was not administered.
Evaluations
One of the trial objectives was to identify possible prognostic
factors of the combined modality treatment (chemotherapy,
surgery and optional radiotherapy). We assessed the association
of OS, event-free survival (EFS; an event comprising PD,
relapse or death), risk of local relapse and risk of distant
metastases with each of 19 potential prognostic factors: baseline
patient characteristics (age, gender, PS, smoking habits, serum
lactate dehydrogenase (LDH) and haemoglobin); baseline tumour
characteristics (histology, tumour stage, differentiation, multilevel
involvement of mediastinal lymph nodes, and nodal enlargement
on CT scan); type of surgery performed (right pneumonectomy,
resection margin and complete resection) and activity of
chemotherapy (clinical response, pathological responses (X95%
and o60%/X60%; this cutoff represented the median amount of
necrosis and fibrosis of all tumours), mediastinal downstaging,
involvement of the uppermost mediastinal lymph node). Response
to chemotherapy was evaluated using WHO criteria and a
complete pathological response was defined as X95% necrosis
and fibrosis. Each patient’s CT scan was assessed by the respective
centre’s medical panel and was reviewed centrally based on the
local reports. After surgery/radiotherapy, patients were seen every
3 months and investigated by CT scan until recurrence or death.
The rate of relapse (local relapse or distant metastases) was
recorded.
Histological diagnosis and assessment of mediastinal lymph
nodes were performed using American Thoracic Society mapping
criteria (Mountain and Dresler, 1997) in all patients. Histology was
reviewed centrally by an experienced pneumopathologist; any
discrepancies were discussed with local pathologists in order to
establish a consensus on the diagnosis. Results of CT scans,
mediastinoscopy and surgical procedures were also reviewed
centrally, based on reports provided.
Statistical analysis
Only patients who underwent surgery after induction chemother-
apy were included in the present analysis. Continuous variables
were analysed by descriptive statistics and categorical variables by
frequency tables. Overall survival was determined from the time
of enrolment to death, while EFS was calculated as the interval
between enrolment and PD, relapse, or death. Cure was defined
as no relapse within 3 years. In some analyses, time to death due
to tumour was calculated as OS; however, with deaths not due to
tumour, patients were censored at their dates of death. Time to
local relapse was similarly defined, ending at the date of
documented local relapse or death due to tumour. Time to distant
relapse was defined as the time between enrolment and
documented metastases or tumour-related death. Time-to-event
variables (e.g. OS, EFS) were estimated using the Kaplan–Meier
method. Comparisons between groups were performed using the
Wilcoxon rank-sum test for continuous variables, the w
2 or
Fisher’s exact test for categorical variables and the log-rank test for
time-to-event variables.
The prognostic impact of certain variables on time-to-event
outcomes was investigated using the Cox proportional hazards
model. The association between an outcome and a potential
prognostic factor was investigated separately for each individual
factor (univariate analysis). The prognostic impact of mediastinal
downstaging (N0–1 vs N2), complete resection and the activity of
chemotherapy on the primary tumour was also investigated in
multivariate analyses including four additional established factors
(age, PS, tumour stage and LDH). All P-values are two-sided. No
correction was performed for multiple evaluations.
RESULTS
Patients and treatments
In total, 90 patients with stage IIIA pN2 NSCLC were enrolled and
were assessable for toxicity and response following docetaxel–
cisplatin chemotherapy (Betticher et al, 2003). Chemotherapy was
well tolerated and active, with 95% of the planned dose and cycles
administered, and an overall response rate of 66% (including
complete remissions in 8% and partial remissions in 58% of
patients; PD was seen in 10% of patients) (Betticher et al, 2003).
In all, 75 patients underwent tumour resection after three cycles
of chemotherapy, with positive resection margin in 16% of patients
(Betticher et al, 2003). Perioperative morbidity and mortality were
low (17 and 3%, respectively). Complete pathological response was
seen in 19% of resected patients. In all, 33 patients (44%) received
radiotherapy, with median total dose 60Gy (range 22–70). Of
these, 23 patients were treated per protocol (i.e. for a positive
margin and/or involvement of the upper lymph node). Nine
patients who were due to receive postoperative radiotherapy did
not actually receive this treatment. Owing to the small numbers
of patients involved, statistical comparison between these patient
groups was considered unfeasible. Table 1 summarises the
characteristics of the 75 patients who underwent surgery, including
the types of resection and response to chemotherapy. All results
presented hereafter relate to this subset of 75 patients unless
otherwise stated.
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After a median observation time of 5 years, the median OS was
35 months (Figure 1) and the median EFS was 15 months;
corresponding survival figures for all 90 patients enrolled were 28
months and 12 months, respectively. Of 47 patients who died, 42
were due to tumour. The median time to death due to tumour was
43 months. At 3 years after initiation of trial therapy (a follow-up
time which all patients reached), 27 patients (36%) were alive and
tumour free (cured). Late toxicities (dyspnoea, chest pain,
myelotoxicity) due to the combined modality treatment were not
seen.
Prognostic factors for survival and cure
Univariate analysis (Table 2) assessing the impact of baseline
patient and tumour characteristics identified only multilevel
involvement of mediastinal lymph nodes as a poor prognostic
Table 1 Characteristics of patients (n¼75), surgery and chemotherapy
Characteristic No. of patients %
Patient characteristics
Gender
Female 17 23
Male 58 77
Age (years); median (range) 59 (39–76)
Performance status
04 5 6 0
12 8 3 7
22 3
Number of pack-years; median (range) 45 (9–160)
Smoking habits
Continued 31 41
Stopped 37 49
Never smoked 7 10
Serum LDH (  ULN); median (range) 0.77 (0.54–3.56)
41 ULN 14 19
Tumour characteristics
Initial histology (pathologist from
participating centres)
Squamous cell carcinoma 32 43
Adenocarcinoma 23 31
Large cell carcinoma 9 12
Poorly differentiated NSCLC 11 14
Tumour stage
16 8
24 4 5 9
32 5 3 3
Mediastinal lymph node enlargement
(41cm) by CT scan
Yes 61 81
No 14 19
Tumour localisation
Upper lobe right 31 42
Middle lobe right 3 4
Lower lobe right 9 12
Upper lobe left 11 15
Lower lobe left 1 1
Central right 10 13
Central left 10 13
Characteristics of the surgery
Type of resection:
Lobectomy/bilobectomy 28/10 37/13
Pneumonectomy (right/left) 21/16 28/22
Complete resection
a
Yes 43 57
No 32 43
Radical resection of the primary
tumour:
Negative margin 63 84
Positive margin 12 16
Activity of the chemotherapy
Response after neoadjuvant
chemotherapy
CR 7 9
PR 48 64
NC 20 27
Table 1 (Continued)
Characteristic No. of patients %
Pathological response on primary
tumour (% of necrosis and fibrosis, two
missing)
Median (range) 60% (0–100%)
X90% 20 27
o20% 12 16
Downstaging of mediastinal lymph
nodes (four missing)
N0 23 32
N1 22 31
N2 26 37
CT¼computed tomography; LDH¼lactate dehydrogenase; NSCLC¼non-small-
cell lung cancer; ULN¼upper limit of normal.
aComplete resection: negative
resection margin (R0) and no involvement of the uppermost mediastinal lymph node
in the mediastinal lymphadenectomy preparation.
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Figure 1 Overall survival (patients who underwent surgery, n¼75).
Prognostic factors in stage IIIA pN2 NSCLC
DC Betticher et al
1101
British Journal of Cancer (2006) 94(8), 1099–1106 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sfactor for OS. Among surgery characteristics, only complete
resection was significantly associated with better OS and EFS. All
factors relating to activity of the chemotherapy were associated
with better OS and EFS. Similar associations were seen when
patients who died from nontumour causes were censored (data not
shown). The prognostic impacts of complete tumour resection,
mediastinal downstaging and pathological response on OS and EFS
were confirmed in multivariate analyses (data not shown).
In a further univariate analysis, prognostic factors for cure were
identified as: clearance of the uppermost mediastinal lymph node
after chemotherapy (23 out of 42 cures in patients with clearance
vs two out of 25 cures in patients without clearance; P¼0.0002);
X60% necrosis and fibrosis in the primary tumour after
chemotherapy (19 out of 37 vs seven out of 33; P¼0.01);
mediastinal downstaging (20 out of 43 vs four out of 25;
P¼0.02) and complete resection (23 out of 41 vs four out of 31;
P¼0.0002). Smoking habits (current or former), PS at start of
therapy and age had no influence on disease evolution.
Localisation of relapses
As the first event, local relapse and distant metastases occurred in
14 out of 75 (19%) and 26 out of 75 (35%) patients, respectively. A
further eight out of 75 (11%) patients had both local relapse and
distant metastases. At longer follow-up, two out of 75 (3%)
patients had local relapse only, six out of 75 (8%) distant relapse
only, 43 out of 75 (57%) had both local and distant relapse, and
24 out of 75 (32%) patients did not develop either relapse. In
univariate analysis, the risk of local relapse and of distant
metastases, including death due to tumour in both cases, was
significantly associated (in terms of lower risk) with complete
tumour resection and chemotherapy activity (CT-assessed clinical
response, pathological response, mediastinal downstaging and
clearance of the uppermost mediastinal lymph node) (Table 2).
Furthermore, there were trends toward increased risk of distant
metastases (P¼0.04) and local relapse (P¼0.07) in patients with a
positive resection margin. The prognostic impacts of complete
tumour resection, pathological response to chemotherapy and
mediastinal downstaging on the risks of developing local and
distant relapses were confirmed in multivariate analyses (Table 3).
The distribution of distant relapses is shown in Table 4.
Interestingly, recurrence occurred most frequently in the lung
(other lobe and/or opposite lung). In all, 10 patients (13%)
developed brain metastases as the first relapse and three (4%) at
later relapses. Of the patients, 10 developed brain metastases
within 12 months of enrolment. Females (five out of 17 vs five out
Table 2 Prognostic factors for overall survival, event-free survival and disease relapse (distant or local): univariate analysis
Overall survival
(months)
Event-free survival
(months) Local relapse (months)
Distant metastases
(months)
Factor Characteristics Median P Median P Median P Median P
Baseline patient characteristics
Overall (months) 35.1 — 14.8 — 29.9 — 18.9 —
1 Age (p59/X60 years) 35.1/30.0 0.40 11.6/15.5 0.66 25.2/30.3 0.53 13.0/24.6 0.45
2 Gender (female/male) 46.1/27.4 0.15 30.3/12.5 0.34 43.3/25.2 0.33 30.3/15.5 0.73
3 PS (0/1–2) 39.0/34.0 0.54 19.5/13.6 0.95 30.3/29.9 0.44 25.9/14.8 0.72
4 Smoking (pack-years p45/445) 39.0/27.4 0.48 14.9/14.8 0.67 31.7/21.2 0.32 21.8/15.5 0.87
Smoking (continued/stopped or never) 29.9/39.0 0.96 12.3/21.1 0.56 16.6/42.1 0.22 14.2/24.6 0.45
5L D H ( p1/41 ULN) 35.1/21.6 0.49 12.3/13.6 0.49 26.3/25.2 0.46 21.8/14.5 0.72
6 Haemoglobin (p/4 134gl
 1
(median)
29.9/43.8 0.38 13.6/25.2 0.29 26.3/43.4 0.17 15.4/27.4 0.34
Baseline tumour characteristics
7 Histology (squamous/
adenocarcinoma+other)
30.0/39.0 0.75 19.2/12.7 0.10 31.7/26.3 0.55 22.8/15.4 0.08
8 Tumour stage (T1–2/T3) 27.6/57.1 0.12 13.7/15.5 0.12 26.3/NR 0.14 21.8/15.5 0.40
9 Differentiation (G1–2/G3) 30.0/46.1 0.69 14.7/14.0 0.58 29.9/26.3 0.98 15.5/18.9 0.73
10 N multilevel (no/yes) 43.4/21.8 0.05 15.5/9.8 0.47 31.7/12.6 0.36 19.5/12.6 0.39
11 N enlargement on CT scan before
chemotherapy (p1cm/41cm)
32.5/29.9 0.47 8.9/12.7 0.71 18.9/26.3 0.72 9.3/15.4 0.50
Characteristics of the surgery
12 Right pneumonectomy (no/yes) 30.0/46.1 0.56 13.6/26.3 0.36 29.9/26.3 0.58 15.6/40.9 0.27
13 Resection margin of primary tumour
(negative/positive)
43.3/16.5 0.10 15.5/11.4 0.11 31.7/15.8 0.07 22.8/12.4 0.04
14 Complete tumour resection
a (yes/no) 62.5/17.3 o0.0001 42.1/9.6 o0.0001 NR/14.4 o0.0001 54.5/13.0 o0.0001
Activity of the chemotherapy
15 Clinical response (CR+PR/NC) 43.8/20.0 0.03 22.8/9.2 0.02 43.3/16.2 0.004 24.6/9.4 0.03
16 Complete pathological response
(X95%) (no/yes)
28.8/NR 0.04 12.4/62.5 0.008 25.2/NR 0.005 15.4/NR 0.006
17 Pathological response (o60%/X60%) 22.4/60.6 0.03 9.0/42.1 o0.0001 16.6/46.9 0.0009 11.7/54.5 o0.0001
18 Mediastinal downstaging (N0/N1/N2) NR/35.1/16.4 0.0001 42.1/15.8/8.6 0.0003 NR/25.2/14.4 o0.0001 NR/19.5/9.3 0.0003
Mediastinal downstaging (N0/N1+N2) NR/22.1 0.001 42.1/11.4 0.008 NR/17.1 0.001 NR/14.2 0.005
Mediastinal downstaging (N0+N1/N2) 57.1/16.4 o0.0001 25.2/8.6 o0.0001 43.8/14.4 o0.0001 26.4/9.3 0.0001
19 Uppermost mediastinal lymph node
involved (no/yes)
62.5/17.3 o0.0001 39.4/9.2 o0.0001 46.9/14.4 o0.0001 43.2/12.2 o0.0001
CR¼complete response; CT¼computed tomography; LDH¼lactate dehydrogenase; N¼node; NC¼no change; NR¼median value not reached; P¼log-rank test P-value;
PD¼progressive disease; PR¼partial response; PS¼performance status; ULN¼upper limit of normal.
aComplete tumour resection: negative resection margin and no
involvement of the uppermost mediastinal lymph node.
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sof 58 males; P¼0.04) and patients with a positive resection margin
(four out of 12 vs six out of 63 with a negative resection margin;
P¼0.05) were at a higher risk of developing brain metastases
within the first 12 months.
Associations of chemotherapy activity and outcomes
As shown in Table 2, all aspects of chemotherapy activity (clinical
response, pathological response, mediastinal downstaging and
clearance of the uppermost mediastinal lymph node) were
significantly associated with improved OS and EFS. Pathological
response (percentage of necrosis and fibrosis) was the most
important feature of the chemotherapy activity on the primary
tumour. The median value of pathological response was 60%; this
was taken as the main cutoff point to dichotomise the variable,
although calculations with other cutoff points were also performed.
In our study, preoperative CT scan was a relatively poor way to
restage patients after neoadjuvant chemotherapy and often
underestimated the degree of local tumour regression. Indeed,
20 patients with stable disease had a median of 47.5% (range
0–100%) necrosis and fibrosis and in three patients a complete
(X95%) pathological response was found. Four patients with
stable disease at resection and without any recurrence within
3 years had a median of 75% (30–100%) necrosis and fibrosis.
Tumours of 26 patients who were relapse-free within 3 years of
enrolment showed a median of 85% (0–100%) necrosis and
fibrosis.
The risk of developing distant metastases was almost zero after
27 months if the chemotherapy induced X60% necrosis/fibrosis in
the tumour (Figure 2A). Conversely, local relapse was seen until
4 years after enrolment, although chemotherapy was active as
shown by the amount of necrosis and fibrosis in the tumour and
mediastinal downstaging (Figure 2B and D). Importantly, for risk
of distant metastases and of local relapse, the hazard ratios of
the group with high pathological response vs the group with low
response decreased as the cutoff point increased (Pp0.01). When
comparing patients who achieved a complete pathological
response (X95% necrosis and fibrosis, the largest cutoff point;
13 (16%) patients) with those who did not, the hazard ratios for
local relapse and for distant metastases were 0.21 and 0.26,
respectively.
DISCUSSION
The final analysis of the study data after a longer follow-up
(median 5 years) confirms and strengthens our previous conclu-
sions (Betticher et al, 2003). The median survival of the 90 patients
included in the trial and for the 75 resected patients was 28 months
and 35 months, respectively. To our knowledge, these are among
the best results obtained in stage IIIA pN2 NSCLC patients. In a
similar group of patients who had received three cycles of cisplatin
Table 3 Multivariate analyses for risk of developing local or distant relapse
Univariate Multivariate model 1 Multivariate model 2 Multivariate model 3
Characteristic N
Hazard
ratio 95% CI P
Hazard
ratio 95% CI P
Hazard
ratio 95% CI P
Hazard
ratio 95% CI P
(a) Prognostic factors for time to local relapse or death due to tumour in univariate and multivariate analyses
Age X60 75 0.83 0.46–1.49 0.53 0.55 0.29–1.05 0.07 0.65 0.35–1.22 0.18 0.771 0.399–1.491 0.44
PS 1–2 75 0.79 0.43–1.45 0.44 0.78 0.37–1.63 0.51 0.95 0.46–1.95 0.89 0.872 0.424–1.794 0.71
Tumour stage 3 75 0.61 0.31–1.19 0.14 0.76 0.35–1.65 0.49 0.49 0.23–1.05 0.06 0.480 0.220–1.047 0.07
LDH 41 ULN 66 1.31 0.64–2.68 0.46 1.23 0.58–2.64 0.59 1.09 0.52–2.29 0.83 1.243 0.590–2.621 0.57
Mediastinal
downstaging
71 0.30 0.16–0.55 0.0001 0.29 0.15–0.59 0.0006 — — — — — —
Complete tumour
resection
75 0.28 0.15–0.52 o0.0001 — — — 0.28 0.14–0.57 0.0003 — — —
Pathological
response X60%
73 0.444 0.242–
0.813
0.0085 — — — — — — 0.523 0.263–1.038 0.06
(b) Prognostic factors for time to distant relapse or death due to tumour in univariate and multivariate analyses
Age X60 75 0.81 0.46–1.41 0.45 0.58 0.32–1.07 0.08 0.72 0.40–1.29 0.27 0.789 0.425–1.461 0.45
PS 1–2 75 1.11 0.63–1.97 0.72 1.08 0.54–2.15 0.84 1.33 0.68–2.59 0.41 1.454 0.727–2.909 0.29
Tumour stage 3 75 0.77 0.41–1.43 0.40 0.94 0.44–1.99 0.87 0.60 0.30–1.22 0.16 0.589 0.280–1.239 0.16
LDH 41 ULN 66 1.14 0.56–2.31 0.72 1.15 0.53–2.51 0.72 1.07 0.51–2.24 0.85 1.099 0.521–2.320 0.80
Mediastinal
downstaging
71 0.34 0.19–0.60 0.0003 0.32 0.16–0.62 0.0008 — — — — — —
Complete tumour
resection
75 0.32 0.17–0.58 0.0002 — — — 0.33 0.18–0.64 0.0009 — — —
Pathological
response X60%
73 0.356 0.199–
0.639
0.0005 — — — — — — 0.347 0.181–0.663 0.001
CI¼confidence interval; LDH¼lactate dehydrogenase; P¼Wald test P-value; PS¼performance status; ULN¼upper limit of normal. CI¼confidence interval; LDH¼lactate
dehydrogenase; P¼Wald test P-value; PS¼performance status; ULN¼upper limit of normal. Although mediastinal downstaging, complete tumour resection and pathological
response (X60%) were associated with overall survival in the univariate analyses, they also correlated with each other. It was not possible to include all of these factors in the
multivariate model (this table presents the updated analysis of our previous report (Betticher et al, 2003)).
Table 4 Sites of distant metastases (at time of first diagnosis and at
longer follow-up) in 75 patients. The site of metastases was documented in
37 of 49 patients, with 1–3 sites per patient (total of 54 sites)
Site
Number of
patients
% of patients/
sites
95% confidence
interval for
patients (%)
Lung and pleura 18 24/33 15–35
Brain 13 17/24 10–28
Lymph nodes 7 9/13 4–18
Liver 6 8/11 3–17
Skeleton 4 5/7 1–13
Skin 3 4/6 0.8–11
Adrenal glands 2 3/4 0.3–9
Peritoneal
carcinoma
1 1/2 0.03–7
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sand gemcitabine preoperatively, the median survival was 18.9
months (Van Zandwijk et al, 2000), while two other trials reported
median survival times of 19 and 22 months for patients with stage
IIIA pN2 NSCLC who received neoadjuvant chemotherapy
(Martini et al, 1993; Rosell et al, 1999).
We sought to identify characteristics of the neoadjuvant
chemotherapy, as well as other prognostic factors, which would
allow enhancement of therapy and help select patients for
thoracotomy. Several factors have been previously described that
predict favourable long-term outcome from a multimodality
approach, including clinical and pathological response to chemo-
therapy, the ability to completely resect the tumour and the
mediastinal lymph nodes, and complete clearance of N2 disease
(Albain et al, 1995; Elias et al, 1997; Burkes et al, 2005). In
agreement with these results, we found that chemotherapy activity
at the primary tumour, mediastinal downstaging and complete
tumour resection (with a negative uppermost mediastinal lymph
node) were strongly associated with improved OS and EFS, and
reduced risk of local and distant relapse. Our identification of
nodal downstaging from N2 to N1 and/or N0 as a powerful
prognostic marker is consistent with findings by Albain et al
(1995), who found that mediastinal nodal downstaging (to N0) was
predictive of improved survival in IIIA/IIIB patients, although
inclusion of preoperative radiotherapy makes it difficult to
evaluate the independent effect of neoadjuvant chemotherapy on
this outcome. Similarly, in a retrospective analysis of 103 patients
who underwent neoadjuvant therapy and resection for stage IIIA
pN2 disease, downstaging to N0 was associated with improved
5-year survival compared with patients who were N2 or N1 after
chemotherapy (no difference in survival was seen between N2 and
N1 patients in this analysis) (Bueno et al, 2000).
We demonstrated that the activity of the chemotherapy on the
tumour and on lymph nodes, as characterised by the amount
of necrosis and fibrosis and clearance of the malignant cells,
respectively, was highly associated with outcomes. Several trials
assessing the role of neoadjuvant chemotherapy, as compared to
local treatment (surgery or radiotherapy), demonstrated a reduc-
tion of the risk of distant metastases (Le Chevalier et al, 1991;
Sause et al, 1995; Dillman et al, 1996; Depierre et al, 2002). To our
knowledge, our data show for the first time that the risk of local
relapse can be reduced in relation to the extent of chemotherapy
activity on the primary tumour. In fact, in patients with X60%
pathological response, the risk of local relapse and distant
metastases was reduced by 56 and 64%, respectively. In patients
with a lesser response, local relapse was frequent (60% of patients)
and occurred up to 4 years after enrolment. Conversely, most cases
of distant metastases were seen within 2 years following enrolment,
after which the risk decreased almost to zero. Therefore, our
efforts should also be concentrated on further reducing the risk of
local relapse alongside reduction of distant metastases.
In our study, the most frequent site of distant metastases was
the lung. This contrasts with the results reported by others who
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Figure 2 Risk of (A) distant metastases stratified by pathological response (percentage of tumour necrosis and fibrosis), (B) distant metastases stratified
by mediastinal downstaging (N0/1 vs N2), (C) local relapse stratified by pathological response and (D) local relapse stratified by mediastinal downstaging.
The risk of developing distant metastases decreased rapidly after 24 months in patients where chemotherapy was active. Conversely, local relapses occurred
throughout the entire observation period.
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sdescribed the brain as the most common site of recurrence (Burkes
et al, 1992, 2005; Albain et al, 1995; Darwish et al, 1995; Choi et al,
1997; Eberhardt et al, 1998; Mamon et al, 2005). Approximately,
40% of patients with stage IIIA NSCLC treated with preoperative
chemotherapy and surgical resection have been reported to
develop brain metastases (Andre et al, 2001; Mamon et al, 2005).
The risk of developing brain metastases appears to be associated
with nonsquamous histology (Robnett et al, 2001; Mamon et al,
2005) and with the type of chemotherapy. Indeed, in one
retrospective analysis, treatment with a taxane – platinum-
containing regimen was associated with a lower risk of brain
metastases than other platinum-based combinations (25 vs 52%,
respectively) (Mamon et al, 2005). Unexpectedly, in our study we
found a lower incidence of brain metastases: 13% as first relapse
site and 3% at later relapse (17% in total); 10 of 13 relapses
occurred within the first 12 months. Female subjects seemed to be
at a higher risk of developing brain metastases. The low number
of cases, however, does not allow further conclusions. The role of
prophylactic cranial irradiation needs to be carefully investigated
and weighed against late toxicity in patients receiving neoadjuvant
docetaxel and cisplatin, as this regimen apparently may reduce the
risk of the development of brain metastases.
Analysis of resected tissue after chemotherapy identified a group
of patients already destined for long-term survival due to tumour
eradication by induction therapy. In these cases, surgical resection
perhaps acted more as a diagnostic and prognostic tool to select
patients for complete resection rather than providing therapeutic
benefit. However, the persistence of malignant cells in the
uppermost mediastinal lymph node following chemotherapy was
associated with a higher risk of local relapse and development of
distant metastases. Moreover, patients without any relapse within
3 years had tumours with a median of 15% viable cells. These
findings suggest that further therapy is crucial for long-term
survival, even in patients who respond to induction chemotherapy;
however, it is not clear whether surgery is the best means to
achieve this. Results from a phase III trial comparing chemother-
apy and radiotherapy with preoperative chemotherapy and
surgical resection in patients with stage IIIA pN2 NSCLC found
no survival differences between treatment arms (Johnstone et al,
2002). In contrast, the final results from a study conducted by the
North American Intergroup, in which patients with stage IIIA
NSCLC were randomised to postinduction resection or further
chemotherapy and radiotherapy following induction with chemor-
adiotherapy, showed improved progression-free survival in the
surgery arm (Albain et al, 2003, 2005). The European Organisation
for Research and Treatment of Cancer (EORTC) study (INT 08941)
randomised patients with nonresectable locally advanced stage
IIIA disease to cisplatin-based induction chemotherapy followed
either by surgery or radiotherapy. Survival was comparable with
either strategy (van Meerbeeck et al, 2005).
The lack of consistent restaging after induction chemotherapy,
and the difficulty in accurately assessing tumour response shortly
after completing the induction treatment, limits the comparability
between studies and strategies. In several studies, and most
notably in the recently reported EORTC trial, patients were
excluded from attempted surgical resection in the absence of a
response to induction therapy. In fact, patients with ‘clinically
stable disease’ following neoadjuvant therapy not uncommonly
have major pathological response at the time of surgery,
as has been observed previously (Albain et al, 1995) and in the
present trial. Clearly, better methods of assessing response after
preoperative therapy are needed. Positron emission tomography
may be a more accurate tool for assessing tumour response and is
currently being prospectively investigated in several trials.
In conclusion, our results with neoadjuvant docetaxel and
cisplatin in patients with locally advanced NSCLC (stage IIIA pN2)
who underwent surgical resection revealed that, after a median
follow-up of 5 years, a cure rate of 36% of resected patients can be
obtained; also, the activity of chemotherapy on the primary
tumour and on mediastinal lymph nodes correlate with improved
OS and EFS, and reduced risk of local relapse and distant
metastases. In addition, we observed a high rate of local relapse,
thereby encouraging the further investigation of radiotherapy in
this patient group. Finally, the risk of brain metastases was lower
than that reported in previous trials.
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